Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer

view original post

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission granted …